Targeting

aAPCs target the naïve and memory T cell repertoire, which has already undergone central tolerance, minimizing the potential for on-target, off-tissue auto-immunity.

Individual aAPCs can be loaded with specific antigens and mixed as multiple tumor-specific antigen cocktails. This approach is designed to maximize polyclonal and cytotoxic T cell activity and minimize the possibility of tumor escape.

Engagement

aAPCs engage directly with targeted T cell receptors. They don’t require processing and presentation by host Dendritic Cells, nor do they require manipulation of the natural T cell genome.

Stimulation

aAPC stimulation of naïve and memory T cell repertoire results in robust, persistent anti-tumor activity and immunologic memory through generation of both Teffector and Tcentral memory populations.

Synthetic

Because aAPCs are synthetic, they cannot be down-regulated by tumor or reprogrammed within the tumor micro-environment (TME).

Combinations

Mechanistically, aAPCs can work in combination to complement other immunotherapeutic approaches that seek to break tolerance at the site of the tumor (CPIs, TKIs.)

Manufacturing

Flexibility and “off-the-shelf” components provide a rapid path to new design and production – novel aAPC-based products can enter clinical testing within months of design.